Patient P-02413
Synthetic patientMETA-24 · Day 125 · 65–74 · F · baseline S16Steering view · 3DOpen companion preview
Therapy response
Unstable
Tolerance
Improving
GI state
Improving
Inflammatory state
Improving
Nutritional resilience
Improving
Discontinuation risk
12%
Trajectory
Baseline → today → 30-day prediction · hover a day for signals and eventssolid = observed · dashed = predicted
- Day 0 META-24 started — Baseline state S16
- Day 28 Trajectory diverged from prediction — Observed response fell below the model's expected path.
What changed?
Trajectory began diverging from predicted response on Day 28.
Primary contributors, last 14 days
- GI instability-15
- Inflammatory activity-13
- Toxicity-10
- Nutritional resilience+9
- Treatment adherence+3
What helped?
No interventions yet.
LIFE OS recommendation
No intervention is indicated right now. The trajectory is stable relative to similar patients. See what worked for similar patients.
Daily trackers
Molecule settingsThe trackers this program marks as important, last 14 days vs the 14 before.
Active minutes
Wearable74 min
worsening · -3.6 vs previous 14 d
Sleep duration
Wearable7 h
stable · -0.1 vs previous 14 d
Energy level
Daily log5.4/10
worsening · -0.2 vs previous 14 d
Steps
Wearable8,158
worsening · -426 vs previous 14 d
GI burden
Companion11.6/100
improving · -2.0 vs previous 14 d
Adherence
Companion85.6 %
stable · +2.2 vs previous 14 d
Sleep quality
Wearable59.9/100
stable · -0.4 vs previous 14 d
Glucose, CGM daily mean
CGM124 mg/dL
stable · +2.7 vs previous 14 d
This trajectory is doing well — what to keep, what to watch
Steering view →Heading towards restoration · 76 from the failing basin, 42 from restoration.
Good elements to keep
- Butyrate producers intacthidden · steering +7.5
- Protein (supports)perturbation · steering +5.8
- Proteinsupporter · GI -3.1 next day
Main detractors to watch
- Bacteroides fragilis elevatedhidden · steering -7.4
- Poor-sleep weekperturbation · steering -3
- Low-HRV stretchperturbation · steering -2.7
- Dietary driftperturbation · steering -2.6
State influencers · digestive
Next-day GI change on high-intake vs low-intake days, last 60 days. Attribution from this patient's own log; sensitivity set by their biology.
- Protein-3.1supporter · 95%
- Ultra-processed food-1.3no signal · 41%
- Dietary fat load-1.2no signal · 38%
- Caffeine-1no signal · 30%
- Simple carbohydrates-0.7no signal · 26%
- Histamine load-0.5no signal · 15%
- Insoluble fibre-0.2no signal · 15%
- Alcohol0no signal · 15%
Biological layers
Which pathways look influenced, and by which layer of this person's biology.
Pathways under pressure
- Inflammatory signalling ↓20
- MicrobiomeBacteroides fragilis expansion
DNA
Fictional pharmacogenomic panel
- CYP2D6 Normal metabolizerExpected exposure
- MTHFR C677TReduced folate turnover
Microbiome
Shannon diversity 4.4 · butyrate capacity 49/100
- Akkermansia muciniphilaNormal
- Faecalibacterium prausnitziiNormal
- Bacteroides fragilisHigh
- Bifidobacterium longumLow
- EnterobacteriaceaeHigh
Wearable, last 14 days
daily evolution fed into the runtime
- HRV
- 67 ms
- Sleep
- 7.0 h
- Steps
- 7,858
- Resting HR
- 58 bpm
Daily log: GI score 12, nutritional resilience 71, adherence 86.
What this patient sees in NostraAI
The content that steers the trajectory: what to eat, what to do, what to take.
What to eat
- Keep meals regular; three to four moderate portions spaced through the day
- Include a cooked vegetable portion with each main meal
- Keep fibre steady; no new sources this week
- Eat slowly and stop at comfortable fullness — smaller volume, more often
What to do
- Log the daily check-in; one line is enough
- Keep the current walking rhythm
- Keep the sleep window steady
- Keep hydration steady: small amounts through the day rather than large volumes at once
What to take
- Take the dose at the same time relative to your evening meal
- No additional supplements this week
- Fictional demo item: continue vitamin D as before
284 biologically similar trajectories
Black: this patient. Green: similar patients whose intervention worked. Orange: similar patients where it did not.
| Patient | Similarity | Baseline | Intervention | Outcome | Response today |
|---|---|---|---|---|---|
| P-02016 | 48% | S20 | DT-01 | improved | 27 |
| P-02331 | 47% | S14 | BR-03 | improved | 34 |
| P-02564 | 35% | S15 | BR-03 | improved | 32 |
| P-02031 | 32% | S12 | AD-05 | improved | 47 |
| P-02479 | 32% | S13 | DT-01 | improved | 48 |
| P-02484 | 32% | S15 | GI-04 | improved | 49 |
| P-02494 | 32% | S09 | GI-04 | improved | 47 |
| P-02391 | 31% | S19 | HY-01 | improved | 53 |
| P-02339 | 30% | S03 | DT-01 | improved | 50 |
| P-02602 | 30% | S20 | HY-01 | improved | 52 |
| P-02685 | 30% | S16 | DT-01 | improved | 47 |
| P-02697 | 30% | S07 | GI-04 | improved | 56 |